EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

A framework for translating tauopathy therapeutics: Drug discovery to clinical trials

Howard H Feldman iD, Jeffrey L Cummings, Adam L Boxer, Adam M Staffaroni, David S Knopman, Stacey J Sukoff Rizzo, Paul R Territo, Steven E Arnold, Clive Ballard, Dirk Beher, Bradley F Boeve, Penny A Dacks und 21 weitere

Alzheimer's & Dementia · 2024-11 · 20 (11) · 8129-8152

DOI: 10.1002/alz.14250 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Alzheimer's & Dementia, online erschienen am 24.09.2024. Verfasst von Howard H Feldman und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences, University of California San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: Tauopathies, Drug Discovery, Clinical Trials as Topic, Biomarkers. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 193 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, NIA NIH HHS, Rainwater Charitable Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The tauopathies are defined by pathological tau protein aggregates within a spectrum of clinically heterogeneous neurodegenerative diseases. The primary tauopathies meet the definition of rare diseases in the United States. There is no approved treatment for primary tauopathies. In this context, designing the most efficient development programs to translate promising targets and treatments from preclinical studies to early‐phase clinical trials is vital. In September 2022, the Rainwater Charitable Foundation convened an international expert workshop focused on the translation of tauopathy therapeutics through early‐phase trials. Our report on the workshop recommends a framework for principled drug development and a companion lexicon to facilitate communication focusing on reproducibility and achieving common elements. Topics include the selection of targets, drugs, biomarkers, participants, and study designs. The maturation of pharmacodynamic biomarkers to demonstrate target engagement and surrogate disease biomarkers is a crucial unmet need. Highlights Experts provided a framework to translate therapeutics (discovery to clinical trials). Experts focused on the “5 Rights” (target, drug, biomarker, participants, trial). Current research on frontotemporal degeneration, progressive supranuclear palsy, and corticobasal syndrome therapeutics includes 32 trials (37% on biologics) Tau therapeutics are being tested in Alzheimer's disease; primary tauopathies have a large unmet need.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TauopathiesDrug DiscoveryClinical Trials as TopicBiomarkersHumansTranslational Research, Biomedicaltau ProteinsDrug Development

Stichwörter der Autor:innen

biomarkersdevelopmentearly‐phase clinical trialspreclinicaltauopathytherapeutics

Substanzen

Biomarkerstau Proteins

Autor:innen und Institutionen

  • Department of Neurosciences, University of California San Diego, La Jolla, California, USA.
  • Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada at Las Vegas, Las Vegas, Nevada, USA.
  • Department of Neurology, Memory and Aging Center, University of California San Francisco, San Francisco, California, USA.
  • Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Aging Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Department of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA.

ORCID-Profile: Howard H Feldman

Förderung

  • NIGMS NIH HHS
  • NIA NIH HHS
  • Rainwater Charitable Foundation

Zitieren

APA

Feldman, H. H., Cummings, J. L., Boxer, A. L., Staffaroni, A. M., Knopman, D. S., Sukoff Rizzo, S. J., Territo, P. R., Arnold, S. E., Ballard, C., Beher, D., Boeve, B. F., Dacks, P. A., Diaz, K., Ewen, C., Fiske, B., Gonzalez, M. I., Harris, G. A., Hoffman, B. J., Martinez, T. N., …, & Rommel, A. (2024). A framework for translating tauopathy therapeutics: Drug discovery to clinical trials. Alzheimer's & Dementia, 20(11), 8129-8152. https://doi.org/10.1002/alz.14250

Vancouver

Feldman HH, Cummings JL, Boxer AL, Staffaroni AM, Knopman DS, Sukoff Rizzo SJ, et al. A framework for translating tauopathy therapeutics: Drug discovery to clinical trials. Alzheimer's & Dementia. 2024;20(11):8129-8152. doi:10.1002/alz.14250

BibTeX
@article{Feldman2024,
  author = {Feldman, Howard H and Cummings, Jeffrey L and Boxer, Adam L and Staffaroni, Adam M and Knopman, David S and Sukoff Rizzo, Stacey J and Territo, Paul R and Arnold, Steven E and Ballard, Clive and Beher, Dirk and Boeve, Bradley F and Dacks, Penny A and Diaz, Kristophe and Ewen, Colin and Fiske, Brian and Gonzalez, M Isabel and Harris, Glenn A and Hoffman, Beth J and Martinez, Terina N and McDade, Eric and Nisenbaum, Laura K and Palma, Jose-Alberto and Quintana, Melanie and Rabinovici, Gil D and Rohrer, Jonathan D and Rosen, Howard J and Troyer, Matthew D and Kim, Doo Yeon and Tanzi, Rudolph E and Zetterberg, Henrik and Ziogas, Nick K and May, Patrick C and Rommel, Amy},
  title = {A framework for translating tauopathy therapeutics: Drug discovery to clinical trials},
  journal = {Alzheimer's & Dementia},
  year = {2024},
  volume = {20},
  number = {11},
  pages = {8129--8152},
  doi = {10.1002/alz.14250}
}
Kostenlos starten →